- Home
- KRRO vs PRLD Comparison
KRRO vs PRLD Comparison
Compare KRRO & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRRO | PRLD |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 69.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRRO | PRLD |
|---|---|---|
| Price | $9.15 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $74.17 | $4.00 |
| AVG Volume (30 Days) | 216.8K | ★ 534.1K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,371,000.00 | ★ $10,500,000.00 |
| Revenue This Year | $144.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $5.20 | $0.61 |
| 52 Week High | $55.89 | $4.22 |
Technical Indicators
Market Signals| Indicator | KRRO | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 63.35 |
| Support Level | $7.82 | $2.37 |
| Resistance Level | $8.14 | $3.00 |
| Average True Range (ATR) | 0.48 | 0.28 |
| MACD | 0.67 | 0.03 |
| Stochastic Oscillator | 95.38 | 79.63 |
Price Performance
Historical ComparisonAbout KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.